meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - breast cancer (mBC)
1
cervical cancer (CC)
classical Hodgkin lymphoma (cHL)
antibody–drug conjugate
trastuzumab deruxtecan
versus all
vs chemotherapy
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
antibody–drug conjugate
trastuzumab deruxtecan
Comparator:
vs chemotherapy;
Risk of bias:
low;
some concerns;
high;
NA;